If you would like to receive Vaxin News please click the following email link with Vaxin News in the subject line.
vaxinnews@vaxin.com
Recent News
HERBERT L. HEYNEKER, PH.D., TO JOIN VAXIN’S BOARD OF DIRECTORS - May 4, 2010
Press Release
VAXIN RECEIVES BIRMINGHAM BUSINESS JOURNAL’S “PACESETTER” AWARD - April 27, 2010
Press Release
VAXIN CEO CREDITS FLU SCARE FOR ’09 GROWTH - April 22, 2010
Birmingham Business Journal
BIRMINGHAM BIOTECH FIRM VAXIN ADDS HEAVY INDUSTRY HITTERS TO BOARD - February 19, 2010
Birmingham Business Journal
VAXIN ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS - February 19, 2010
Press Release
VAXIN DEAL MAY SIGNAL MATURATION OF BIRMINGHAM BIOTECH INDUSTRY - October 23, 2009
Birmingham Business Journal
VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA- October 14, 2009
Press Release
VAXIN PANDEMIC VACCINE PHASE I RELEASE- July 17, 2009
Press Release
VAXIN TECH 50 RELEASE- June 15, 2009
Press Release
WHAT'S ON THE HORIZON FOR A SWINE FLU VACCINE - May 6, 2009
getbetterhealth.com
VAXIN COMPLETES DOSING OF PHASE 1 HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE- February 24, 2009
Press Release
VAXIN RECEIVES $1.4 MILLION FOR ANTHRAX VACCINE DEVELOPMENT- December 10, 2008
Press Release
VAXIN AND CRUCELL ANNOUNCE COLLABORATION TO FIGHT ALZHEIMER’S DISEASE- November 13, 2008
Press Release
VAXIN TO PRESENT AT THE RODMAN & RENSHAW 1OTH ANNUAL
HEALTHCARE CONFERENCE - November 5, 2008
Press Release
Vaxin begins pandemic flu study using Birmingham volunteers - October 8, 2008
The Birmingham News
VAXIN INITIATES PHASE I HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE - October 8, 2008
Press Release
VAXIN RECEIVES $100,000 GRANT FOR DEVELOPMENT OF ACNE VACCINE- September 18, 2008
Press Release
VAXIN AWARDED NIH FUNDING FOR AVIAN FLU VACCINE DEVELOPMENT- September 10, 2008
Press Release
Vaxin developing game-changing flu vaccine
- August 26, 2008
TechJournal South
VAXIN’S PANDEMIC VACCINE SPOTLIGHTED- August 13, 2008
Promising data presented at Immunotherapeutics & Vaccine Summit
Press Release
Vaxin Welcomes New CEO
- August 8, 2008
New Leader To Advance Company’s Product Pipeline Into Clinical Development
Press Release
Biotech firm Vaxin taps new CEO, looks for VC funds - August 8, 2008
Birmingham Business Journal
Media Coverage
E. coli-Vectored Tetanus and Anthrax Vaccine Patch Protective in Mice - July 4,
2006
Link to
article
Vaxin executives eye Taiwan for money, location incentives - February 17,
2006
Link to article
(Taiwan) Vaxin's approach a 'new vision' for the vaccine industry: CEO (Taiwan Life
Sciences Weekly - January 16, 2006
Link to article
Vaxin’s technology at the forefront of national development trends for 2004 -
January 11, 2005
Link to article
New targets for anthrax remedies (SeparationsNOW.com)-December
2004
Link to article
Federal Funding is Key to vaccine producer Vaxin (Birmingham Business Journal) -Oct. 22,
2004
Link to article
Press Releases
Data from Vaxin’s First Flu Vaccine Clinical Trial Reported in Journal “Vaccine” -Jan.
11, 2005
Birmingham, AL – January 11, 2005 – Vaxin Inc., a privately-held biotechnology company, has
demonstrated, in a Phase I human clinical study, that the company’s recombinant influenza vaccine
provides a potential alternative to traditional flu vaccines. Published in the January 11, 2005 issue of
the journal Vaccine (volume 23, issue 8, pages 1029-1036), the paper is entitled “Safety and
immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.” The
authors conclude that Vaxin’s novel flu vaccine, which is produced in cell culture, was immunogenic
and well tolerated by human volunteers.
Link to whole article
Revolutionary Flu Vaccine in Development by Vaxin Inc.-Oct. 11,
2004
Birmingham, AL – October 11, 2004 – In the midst of mounting concerns about shortages of flu vaccine supplies and worries about
the deadly avian flu virus and its potential to cause a pandemic, Vaxin Inc., a privately-held biotechnology company in Birmingham,
Alabama, is quietly developing a revolutionary new flu vaccine. The Vaxin influenza vaccine differs from traditional flu vaccines in two
important ways: its method of manufacture and its method of delivery; both of which convey potentially significant advantages over
traditional flu vaccines.
Link to whole article
Crucell And Vaxin Announce PER.C6 Licensing Agreement-Sept. 13,
2004
Birmingham, AL – Sept. 13, 2004 – Vaxin Inc., an emerging biotechnology company developing
new vaccines for influenza, anthrax, respiratory syncytial virus (RSV) and other diseases,
announced today that it has entered into a license agreement with Dutch biotechnology company
Crucell N.V. (Euronext, NASDAQ: CRXL). This non-exclusive license agreement allows Vaxin to
use Crucell’s PER.C6® cell line for the development, manufacture and commercialization of its
recombinant adenoviral vaccines against certain respiratory viruses.
Link to whole article
Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral
Vaccine-Sept. 13, 2004
Leiden, The Netherlands, September 13, 2004 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced
today that it has signed a non-exclusive PER.C6® technology license agreement with Vaxin, Inc. of Birmingham, Alabama. This license
agreement allows Vaxin to use PER.C6® technology for research, development and commercialization of recombinant adenoviral vaccines
against certain respiratory viruses.
Link to whole article
CLICK HERE FOR ALL VAXIN
NEWS ARCHIVES